Literature DB >> 21115084

Type 2 metabotropic glutamate receptor (mGluR2) fails to negatively couple to cGMP in stably transfected cells.

Barbara Wroblewska1, Iga N Wegorzewska, Tomasz Bzdega, Joseph H Neale.   

Abstract

The group II metabotropic glutamate receptors 2 and 3 (mGluR2 and mGluR3) share sequence homology, common pharmacology and negative coupling to cAMP. We recently discovered that mGluR3 also is negatively coupled through a G-protein to the cGMP transduction pathway in rat cerebellar granule cells and astrocytes. To test the hypothesis that mGluR2 also has access to the cGMP pathway, C6 glioma cells were stably transfected with mGluR2 and mGluR3 cDNA and their coupling to cGMP levels was characterized. In contrast to many other cell lines, C6 has a robust cGMP response that makes it attractive in the study of receptor coupling to this second messenger pathway. Consistent with prior studies, the mGluR3 receptor was negatively coupled to cGMP and this coupling was blocked by PTX. In contrast, mGluR2 agonists failed to reduce sodium nitroprusside stimulated cGMP levels in transfected cell lines where the receptor was negatively coupled to cAMP. These data provide further support for the functional divergence between these two closely related receptors. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115084      PMCID: PMC3021184          DOI: 10.1016/j.neuint.2010.11.012

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  23 in total

Review 1.  Modelling G-protein-coupled receptors for drug design.

Authors:  D R Flower
Journal:  Biochim Biophys Acta       Date:  1999-11-16

Review 2.  G protein specificity: traffic direction required.

Authors:  Paul R Albert; Liliane Robillard
Journal:  Cell Signal       Date:  2002-05       Impact factor: 4.315

Review 3.  Physiological roles and therapeutic potential of metabotropic glutamate receptors.

Authors:  P Jeffrey Conn
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

Review 4.  Sensing G protein-coupled receptor activation.

Authors:  Manuela Ambrosio; Alexander Zürn; Martin J Lohse
Journal:  Neuropharmacology       Date:  2010-08-18       Impact factor: 5.250

5.  LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors.

Authors:  D D Schoepp; B G Johnson; R A Wright; C R Salhoff; N G Mayne; S Wu; S L Cockerman; J P Burnett; R Belegaje; D Bleakman; J A Monn
Journal:  Neuropharmacology       Date:  1997-01       Impact factor: 5.250

6.  N-acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells.

Authors:  B Wroblewska; J T Wroblewski; O H Saab; J H Neale
Journal:  J Neurochem       Date:  1993-09       Impact factor: 5.372

7.  Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human beta2-adrenoceptors overexpressed in mouse heart.

Authors:  Jürgen F Heubach; Ursula Ravens; Alberto J Kaumann
Journal:  Mol Pharmacol       Date:  2004-05       Impact factor: 4.436

8.  Pharmacological characterization of metabotropic glutamate receptors in cultured cerebellar granule cells.

Authors:  E Aronica; F Nicoletti; D F Condorelli; R Balázs
Journal:  Neurochem Res       Date:  1993-05       Impact factor: 3.996

9.  Temporal and depolarization-induced changes in the absolute amounts of mRNAs encoding metabotropic glutamate receptors in cerebellar granule neurons in vitro.

Authors:  M R Santi; S Ikonomovic; J T Wroblewski; D R Grayson
Journal:  J Neurochem       Date:  1994-10       Impact factor: 5.372

Review 10.  The metabotropic glutamate receptors: structure and functions.

Authors:  J P Pin; R Duvoisin
Journal:  Neuropharmacology       Date:  1995-01       Impact factor: 5.250

View more
  6 in total

Review 1.  Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family.

Authors:  Joseph H Neale; Rafal T Olszewski; Daiying Zuo; Karolina J Janczura; Caterina P Profaci; Kaleen M Lavin; John C Madore; Tomasz Bzdega
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

2.  Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia.

Authors:  Caterina P Profaci; Kristyn A Krolikowski; Rafal T Olszewski; Joseph H Neale
Journal:  Psychopharmacology (Berl)       Date:  2011-02-16       Impact factor: 4.530

3.  Group II metabotropic glutamate receptor interactions with NHERF scaffold proteins: Implications for receptor localization in brain.

Authors:  Stefanie L Ritter-Makinson; Maryse Paquet; James W Bogenpohl; Rachel E Rodin; C Chris Yun; Edward J Weinman; Yoland Smith; Randy A Hall
Journal:  Neuroscience       Date:  2017-04-07       Impact factor: 3.590

4.  Immunohistological and electrophysiological evidence that N-acetylaspartylglutamate is a co-transmitter at the vertebrate neuromuscular junction.

Authors:  Kathryn K Walder; Steve B Ryan; Tomasz Bzdega; Rafal T Olszewski; Joseph H Neale; Clark A Lindgren
Journal:  Eur J Neurosci       Date:  2012-11-08       Impact factor: 3.386

5.  Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia.

Authors:  Daiying Zuo; Tomasz Bzdega; Rafal T Olszewski; John R Moffett; Joseph H Neale
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

6.  NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation.

Authors:  Toshihiko Yamada; Daiying Zuo; Tatsuo Yamamoto; Rafal T Olszewski; Tomasz Bzdega; John R Moffett; Joseph H Neale
Journal:  Mol Pain       Date:  2012-09-12       Impact factor: 3.395

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.